

IPO Note

19th October 2026

Paras Healthcare Limited



Retail Research	IPO Note
Sector: Healthcare Services (Hospitals)	Price Band (Rs): 660 – 693
19 th October 2026	Recommendation: NEUTRAL

Paras Healthcare Ltd.

Company Overview:

Paras Healthcare Ltd. (PHL) is a multi-specialty healthcare provider focused on delivering affordable and advanced medical care across North India under the Paras Health brand. The company operates a network of hospitals across key underserved markets offering a comprehensive range of services spanning cardiology, oncology, neurosciences, orthopedics, nephrology, gastroenterology and critical care. As of Jun'26, Paras Healthcare manages 8 hospitals with 2,211 operational beds across Delhi NCR, Haryana, Bihar, Jharkhand and Uttar Pradesh, serving patients through a hub-and-spoke healthcare delivery model. The company has established a strong presence in Tier-II and Tier-III cities enabling access to quality healthcare while maintaining a comparatively asset-efficient operating structure. Supported by a team of experienced medical professionals, Paras Healthcare has demonstrated consistent growth in patient volumes and occupancy levels driven by capacity expansion, specialty-led service offerings and increasing healthcare penetration in its core markets.

Key Highlights:

1. Established regional healthcare franchise with strong brand recall: PHL has built the Paras Health brand over nearly two decades operating a network of 8 hospitals with over 2,000 operational beds across North India. The company has developed strong positioning in key catchment markets such as NCR, Bihar, Jharkhand and Eastern Uttar Pradesh, driving patient referrals and repeat visits.

2. High-acuity specialty mix supports superior realizations: The company's core CONGOR specialties comprising Cardiac Sciences, Oncology, Neuro Sciences, Gastro Sciences, Orthopaedics and Renal Sciences contributed 74.7% of FY26 revenue. Among these, Oncology (21.6%), Neuro Sciences (13.0%) and Cardiac Sciences (12.8%) were the largest contributors. The focus on complex and specialized medical procedures supports higher realizations, strengthens competitive positioning and enhances the company's ability to attract and retain quality medical talent.

3. Improving asset utilization across hospital network: PHL has demonstrated strong improvement in operating metrics with bed occupancy increasing to 61.8% in FY26 from 50.8% in FY25 while occupied bed days grew 25.8% YoY to 3,38,321. The improvement reflects stronger patient throughput, increasing acceptance of its specialty offerings and better utilization of existing infrastructure, providing headroom for growth without significant incremental capital deployment.

4. Visible expansion pipeline to drive future growth: PHL plans to expand its bed capacity from 2,211 beds as of Jun'26 to 3,011 beds by FY28 backed by an identified pipeline comprising a 300-bed Gurugram hospital scheduled for commissioning in FY27 and a 500-bed Ludhiana hospital expected to commence operations in FY28. The planned additions are expected to strengthen the company's presence across North India while supporting medium-term revenue growth and operating leverage.

View & Valuation: Paras Healthcare Ltd. is a leading multi-specialty hospital chain with a strong presence across North India focused on underserved Tier-II and Tier-III markets. The company derived 74.7% of its FY26 revenue from high-acuity specialties supporting strong realizations and profitability. The company reported Revenue/EBITDA CAGR of 19.3%/62.1% respectively over FY24-FY26 with EBITDA margin expanding from 10.5% to 19.5% over the same period driven by improving occupancy and operating leverage while also turning profitable on a net basis. At the upper price band of Rs 693, the issue is valued at an EV/EBITDA multiple of 24.1x on post-issue capital. Going forward, growth is expected to be supported by rising occupancy in newer hospitals, expansion of high-acuity specialties and planned capacity additions at Gurugram and Ludhiana. However, the company's high dependence on government schemes and PSU patients coupled with regulatory and pricing-related uncertainties in the healthcare sector remains a key monitorable. While the company is well positioned to benefit from increasing healthcare demand in its operating regions, we assign a NEUTRAL rating to the issue and would like to track occupancy levels, execution of upcoming capacity additions and the impact of regulatory developments over the next few quarters post listing.

Issue Details	
Date of Opening	21st October 2026
Date of Closing	23rd October 2026
Price Band (Rs)	660 – 693
Issue Size (Rs cr)	1,450
No. of shares	2,09,23,520 @Upper Price Band
Fresh Issue (Rs cr)	500
Offer for Sale (Rs cr)	950
Face Value (Rs)	1
Post Issue Market Cap (Rs cr)	7,165 – 7,498
BRLMs	JM Financial Ltd, BofA Securities India Ltd and Nuvama Wealth Management Ltd
Registrar	MUFG Intime India Pvt Ltd
Bid Lot	21 shares and in multiples thereof
QIB shares	75%
Retail shares	10%
NII shares	15%

Objects of Issue	
Particulars (Rs cr)	Estimated utilization from net proceeds
Prepayment or scheduled re-payment, in full or part, of certain outstanding borrowings availed by the company	320.9
Investment in wholly owned subsidiary, PMHPL for repayment/prepayment of borrowings, in full or part, of PMHPL	54.1
General corporate purposes*	-
Net proceeds from fresh issue*	-

*The amount utilized for general corporate purposes shall not exceed 25% of the Gross Proceeds.

Shareholding Pattern		
Pre-Issue	No. of Shares	%
Promoter & Promoter Group	7,35,19,240	72.8
Public & Others	2,74,66,947	27.2
Total	10,09,86,187	100.0

Post Issue @ Upper Price Band	No. of Shares	%
Promoter & Promoter Group	6,91,90,236	63.9
Public & Others	3,90,10,959	36.1
Total	10,82,01,194	100.0

Source: RHP, SBICAP Securities Research

Selling shareholder via OFS	Classification	No. of shares
Dr. Dharminder Kumar Nagar	Promoter	43,29,004
Commelina Ltd	Investor	93,79,509
Total @Upper Price Band		1,37,08,514

Key Financials

Particulars (Rs cr)	FY24	FY25	FY26	1QFY27
Revenue from operations	1,129	1,294	1,606	470
EBITDA	119	136	313	105
EBITDA Margin (%)	10.5	10.5	19.5	22.3
PAT	(15)	(58)	44	50
PAT Margin (%)	(1.4)	(4.5)	2.7	10.6
EPS	(1.5)	(5.7)	4.3	4.9
Adj. PAT	(29)	(58)	44	50
Adj. PAT Margin (%)	(2.5)	(4.5)	2.7	10.6
Adj. EPS	(2.8)	(5.7)	4.3	4.9
RoE (%)	(8.5)	(20.7)	11.1	-
RoCE (%)	8.3	4.1	15.4	-
P/E (x)*	(243.7)	(120.7)	159.7	-
EV/EBITDA*	62.0	55.2	24.1	-

*Note: Pre-issue P/E and EV/EBITDA based on upper price band

Source: RHP, SBICAP Securities Research


Risk Factors

- **High geographic concentration exposing to regional risks:** The company derived 66.1% of revenue from North India hospitals in FY26 with the Gurugram and Panchkula hospitals together contributing 49.5% of revenues. Any adverse developments in these key markets could materially impact the company's operations and financial performance.
- **Large contingent liabilities may impact financial position:** The company had outstanding contingent liabilities of Rs 398 cr as of Jun'26, equivalent to ~91.5% of its net worth. Any adverse outcome relating to these matters could impact earnings and cash flows.
- **Expansion plans carry execution risk:** The company plans to expand bed capacity by 36.2% from 2,211 beds in FY26 to 3,011 beds by FY28 through upcoming hospitals in Gurugram and Ludhiana. Delays in commissioning, lower-than-expected occupancy or cost overruns could impact returns from these investments.
- **Dependence on government schemes:** Government schemes and PSU patients contributed 41.3% of revenue in FY26. Delays in reimbursements, changes in government healthcare policies, or suspension of empanelment could adversely impact cash flows, working capital requirements and profitability.
- **High employee attrition:** PHL reported an employee attrition rate of 60.4% in FY26. Any inability to attract and retain doctors, nurses and other healthcare professionals could adversely impact service quality and operational efficiency.
- **Regulatory Risk and Price Capping:** Vulnerability to evolving regulatory price controls and trade margin caps on pharmaceuticals and medical consumables. Recent interventions by the National Pharmaceutical Pricing Authority (NPPA) such as capping trade margins at 30% on 137 non-scheduled anti-cancer drugs and potential broader price controls pose a structural risk that could compress high-margin pharmacy billings and profits.

Growth Strategies

- Driving occupancy and operating leverage across the existing network by improving patient throughput, increasing doctor productivity and scaling newer hospitals toward maturity.
- Strengthening high-acuity offerings across CONGOR specialties to drive hospital utilization and sustainable growth.
- Expanding bed capacity through a disciplined asset-light model with plans to increase capacity from 2,211 beds in FY26 to 3,011 beds by FY28 through the addition of new hospitals in Gurugram and Ludhiana.
- Expanding presence in underserved North Indian markets with low bed density and limited access to tertiary and quaternary healthcare services leveraging the company's established regional brand and operating track record.
- Enhancing revenue per patient through a broader specialty mix, increased penetration of insurance and corporate patients and continued focus on complex procedures with superior realizations.

Journey of Network Expansion



Notes:

(1) Source: CRISIL Report

(2) Gurugram Hospital commenced operations with an initial bed capacity of 200 beds.


(3) Udaipur Hospital commenced operations with a bed capacity of 200 beds in 2019 and Ranchi Hospital expanded its bed capacity with 300 beds in FY23.

Comprehensive Clinical Offerings

SPECIALITY	GURUGRAM	PATNA	DARBHANGA	PANCHKULA	UDAIPUR	RANCHI	SRINAGAR	KANPUR
Cardiac Sciences								
Cardio Thoracic Vascular Surgery	✓	✓	✗	✓	✓	✓	✓	✓
Cardiology	✓	✓	✓	✓	✓	✓	✓	✓
Oncology								
Medical Oncology	✓	✓	✓	✓	✓	✓	✓	✓
Radiation Oncology	✓	✓	✗	✓	✓	✓	✗	✓
Surgical Oncology	✓	✓	✗	✓	✓	✓	✓	✓
Hemato Oncology & Bone Marrow Transplant	✓	✓	✗	✓	✗	✗	✗	✗
Nuclear Medicine	✓	✓	✗	✓	✗	✓	✗	✓
Neuro Sciences								
Neurosurgery	✓	✓	✓	✓	✓	✓	✓	✓
Neuro Intervention	✓	✓	✗	✓	✓	✓	✓	✓
Neurology	✓	✓	✓	✓	✓	✓	✓	✓
Spine Surgery	✓	✓	✗	✓	✓	✓	✓	✓
Gastro Sciences								
Gastroenterology	✓	✓	✓	✓	✓	✓	✓	✓
Gastrointestinal Surgery	✓	✓	✗	✓	✗	✓	✓	✓
Liver Transplant	✓	✓	✗	✗	✗	✗	✗	✗
Orthopedics								
Orthopedics & Sports Injury	✓	✓	✓	✓	✓	✓	✓	✓
Renal Sciences								
Nephrology	✓	✓	✓	✓	✓	✓	✓	✓
Urology	✓	✓	✓	✓	✓	✓	✓	✓
Kidney Transplant	✓	✓	✗	✓	✗	✗	✗	✗
Other Specialties								
General & Minimal Access Surgery	✓	✓	✓	✓	✓	✓	✓	✓
Obstetrics	✓	✗	✓	✗	✓	✓	✓	✗
Gynecology	✓	✓	✓	✓	✓	✓	✓	✓
Paediatrics	✓	✓	✓	✓	✓	✓	✓	✓
Internal Medicine	✓	✓	✓	✓	✓	✓	✓	✓
Pulmonology	✓	✓	✓	✓	✓	✓	✓	✓
Ear, Nose & Throat (ENT)	✓	✓	✓	✓	✓	✓	✓	✓
Plastic & Reconstructive Surgery	✓	✓	✓	✓	✓	✓	✓	✓
Endocrinology	✓	✓	✓	✓	✓	✗	✓	✓

Source: RHP, SBICAP Securities Research

Hospital Network



Source: RHP, SBICAP Securities Research

Operational KPIs

Particulars	FY24	FY25	FY26	1QFY27
Number of operational beds ⁽¹⁾	1,332	1,465	1,502	1,502
Bed occupancy rate (%) ⁽²⁾	52.5%	50.8%	61.8%	69.7%
ARPOB (Rs per day) ⁽³⁾	44,306	48,089	47,398	49,352
Occupied Bed Days ⁽⁴⁾	2,54,716	2,68,927	3,38,321	95,272
Average Length of Stay (days) ⁽⁵⁾	3.1	2.9	2.9	2.8

(1) Operational beds are the number of hospital beds that are fully functional and available for in-patient midnight occupancy, including census beds (such as ICU and ward beds) and excluding non-census beds (such as day-care, dialysis, and emergency beds).

(2) Bed occupancy rate is calculated as the periodic average of occupied beds as a percentage of the periodic average of operational beds. Periodic average of occupied beds is calculated as an average of monthly occupied beds. Periodic average of operational beds is calculated as an average of monthly operational beds.

(3) ARPOB (Average Revenue Per Occupied Bed) is calculated as revenue from operations less other operating revenue divided by the number of occupied bed days for the period.


(4) Occupied Bed Days (OBD) are the total number of inpatient bed-days utilized during the relevant period and is calculated as the sum of occupied beds recorded at each midnight census during the period.

(5) ALOS refers to the average number of days an in-patient occupies a hospital bed during a specified period and is calculated as Occupied Bed Days divided by In-Patient Volume for the period. Occupied Bed Days is calculated as the sum of occupied beds recorded at each midnight census during the period.

Source: RHP, SBICAP Securities Research

Revenue Growth Across Hospital Cohorts

Growth in Revenue from Operations



Source: RHP, SBICAP Securities Research



Revenue Split - Payor Category Wise

Particulars	FY24		FY25		FY26		1QFY27	
	Revenue (Rs cr)	% of Revenue	Revenue (Rs cr)	% of Revenue	Revenue (Rs cr)	% of Revenue	Revenue (Rs cr)	% of Revenue
Self Pay	459	40.6%	531	41.0%	544	33.9%	147	31.3%
Insurance/TPAs	334	29.6%	363	28.1%	399	24.8%	118	25.1%
Government Schemes and PSUs	336	29.8%	400	30.9%	663	41.3%	205	43.6%
Total	1,129	100.0%	1,294	100.0%	1,606	100.0%	470	100.0%

Source: RHP, SBICAP Securities Research

Margin Expansion Journey

Growth in Operating EBITDA⁽¹⁾



1. Operating EBITDA is calculated as profit or loss before tax plus finance costs and depreciation and amortization expense, less fair value gain on financial instruments and other income.

2. Corporate costs for the three months period ended June 30, 2026 and June 30, 2025 and Fiscals 2026, 2025 and 2024 amounting to Rs 107.91 mn, Rs 62.28 mn, Rs 280.50 mn, Rs 299.27 mn and Rs 287.15 mn, respectively, have been allocated to Operating EBITDA for mature and Emerging Hospitals in the chart above.

Source: RHP, SBICAP Securities Research

Revenue From Sale of Pharmacy Product

Particulars	FY24		FY25		FY26	
	Revenue (Rs cr)	% of Revenue	Revenue (Rs cr)	% of Revenue	Revenue (Rs cr)	% of Revenue
Revenue from sale of product - Pharmacy	42	3.7%	47	3.7%	61	3.8%

Source: RHP, SBICAP Securities Research

Healthcare Infrastructure Metrics

Particulars	FY24	FY25	FY26	1QFY27
Number of hospitals ⁽¹⁾	8	8	8	8
Total bed capacity ⁽²⁾	2,135	2,135	2,211	2,211
Number of ICU beds ⁽³⁾	425	466	559	559
Operational beds ⁽⁴⁾	1,332	1,465	1,502	1,502
ALOS (days) ⁽⁵⁾	3.1	2.9	2.9	2.8
In-patient volume ⁽⁶⁾	81,047	93,170	1,15,496	34,354
Out-patient volume ⁽⁷⁾	5,69,139	6,38,193	7,78,707	2,25,734
Capex per bed (Rs cr) ⁽⁸⁾	0.6	0.7	0.8	0.8
Number of surgeries ⁽⁹⁾	30,219	33,072	39,687	11,112

(1) Number of hospitals refer to the total number of hospitals operated by the Company and our Subsidiaries at the end of the relevant period / year.

(2) Total bed capacity denotes the number of beds for which the civil structure has been planned for at the end of the period / year.

(3) Number of ICU beds represents the total intensive care unit beds operational as of the end of the relevant period / year.

(4) Operational beds are the number of hospital beds that are fully functional and available for in-patient midnight occupancy, including census beds (such as ICU and ward beds) and excluding non-census beds (such as day-care, dialysis, and emergency beds). Hospital-wise operational beds are fully functional hospital beds that are available for in-patient midnight occupancy, including census beds (such as ICU and ward beds) and excluding non-census beds (such as day-care, dialysis, and emergency beds) for the specific hospital.

(5) ALOS refers to the average number of days an inpatient occupies a hospital bed during a specified period and is calculated as the Occupied Bed Days divided by in-patient volumes for the period. Occupied Bed Days is calculated as the sum of occupied beds recorded at each midnight census during the period.

(6) In-patient volumes refer to the total number of patients who have been admitted to a healthcare facility for treatment and subsequently discharged during the relevant period / year.

(7) Out-patient volumes refer to the total number of outpatient visits for consultations within a specific period. Outpatient means patients that receive diagnosis and treatment without being admitted overnight or for day-care procedures.

(8) Capital expenditure per bed is calculated as the aggregate of gross block of property, plant and equipment and right of use assets as appearing in Restated Consolidated Financial Information as at the end of the relevant period / year divided by the total bed capacity as of the end of the relevant period / year.

(9) Number of surgeries represents the sum total of all types of surgeries performed in a relevant period / year at all hospitals.

Source: RHP, SBICAP Securities Research

Hospital - Operating Models

Particulars	Gurugram Hospital	Patna Hospital	Darbhanga Hospital	Panchkula Hospital	Udaipur Hospital	Ranchi Hospital	Srinagar Hospital	Kanpur Hospital
Operating model	Owned	Partial fixed rent and partial revenue share	Revenue share	Partial fixed rent and partial revenue share	Owned	Partial fixed rent and partial revenue share	Fixed rent	Fixed rent
Commencement of operations	Jun-06	Jul-13	Mar-16	Nov-18	Oct-19	Sep-19	Jun-23	Apr-24
Contract tenure	NA	32 years	30 years	30 years	NA	35 years with renewal options	15 years with option to renew	30 years with option to renew
Total bed capacity as of Jun 30, 2026	300	392	100	284	200	300	200	435
Capital expenditure per bed (Rs cr)	0.8	0.7	0.4	0.8	0.9	0.7	0.8	0.7

Source: RHP, SBICAP Securities Research

Hospital Cohort Performance

Particulars	FY24	FY25	FY26	1QFY27
Revenue by Hospital Cohort (Rs cr)				
Mature Hospitals	928	1,011	1,180	315
Emerging Hospitals	166	214	283	91
New Hospitals	35	69	144	64
Bed Occupancy (%)				
Mature Hospitals	65.8%	66.1%	73.3%	74.8%
Emerging Hospitals	41.6%	48.9%	57.8%	66.9%
New Hospitals	10.2%	11.3%	33.8%	58.7%

Source: RHP, SBICAP Securities Research

Hospital-wise Capacity Overview

Hospital	FY24		FY25		FY26		1QFY27	
	Bed Capacity ⁽¹⁾	Op. Beds ⁽²⁾	Bed Capacity ⁽¹⁾	Op. Beds ⁽²⁾	Bed Capacity ⁽¹⁾	Op. Beds ⁽²⁾	Bed Capacity ⁽¹⁾	Op. Beds ⁽²⁾
Gurugram	300	250	300	250	300	235	300	235
Patna	350	269	350	269	392	309	392	309
Darbhanga	100	79	100	79	100	79	100	79
Panchkula	250	220	250	220	284	230	284	230
Udaipur	200	169	200	169	200	169	200	169
Ranchi	300	177	300	177	300	177	300	177
Srinagar	200	168	200	168	200	168	200	168
Kanpur	435	-	435	133	435	135	435	135
Total	2,135	1,332	2,135	1,465	2,211	1,502	2,211	1,502

Note: Op. Beds – Operational Beds.

(1) Total bed capacity denotes the number of beds for which the civil structure has been planned for at the end of the relevant period / year.

(2) Operational beds are the number of hospital beds that are fully functional and available for in-patient midnight occupancy, including census beds (such as ICU and ward beds) and excluding non-census beds (such as day-care, dialysis, and emergency beds).

Source: RHP, SBICAP Securities Research

Clinical Specialty Revenue Mix

Specialty	FY24		FY25		FY26		1QFY27	
	Rev. (Rs cr)	% of Rev.	Rev. (Rs cr)	% of Rev.	Rev. (Rs cr)	% of Rev.	Rev. (Rs cr)	% of Rev.
Cardiac sciences	149	13.2%	152	11.7%	205	12.8%	63	13.3%
Oncology	213	18.9%	257	19.9%	347	21.6%	91	19.4%
Neuro sciences	171	15.1%	196	15.1%	209	13.0%	59	12.5%
Gastro sciences	58	5.1%	84	6.5%	133	8.3%	39	8.2%
Orthopedics and sports injury	139	12.3%	138	10.6%	173	10.8%	57	12.1%
Renal sciences	86	7.7%	104	8.1%	132	8.2%	41	8.7%
Revenue from CONGOR specialities	817	72.3%	931	71.9%	1,200	74.7%	350	74.4%
Others	312	27.7%	363	28.1%	406	25.3%	121	25.7%
Total	1,129	100.0%	1,294	100.0%	1,606	100.0%	470	100.0%


Note: Rev. - Revenue

(1) Includes, among others, specialties such as general and minimal access surgery, obstetrics, gynaecology, paediatrics, internal medicine, pulmonology, ear, nose and throat (ENT), plastic and reconstructive surgery, ophthalmology, dentistry, dermatology, cosmetology, psychiatry, physiotherapy and endocrinology.

Source: RHP, SBICAP Securities Research


Industry Overview

Healthcare delivery market in North India (Rs trillion)



Source: RHP, SBICAP Securities Research

Healthcare delivery market in East India (Rs trillion)



Source: RHP, SBICAP Securities Research

Peer Comparison – Financials (FY26)

Particulars (Rs cr)	Paras Healthcare	Yatharth Hospital and Trauma Care Services	Global Health	Max Healthcare Institute	Jupiter Life Line Hospitals
CMP (Rs)	693	985	1,246	848	247
Mkt Cap.	7,498	9,491	33,515	82,527	8,088
Enterprise Value	7,550	9,481	33,016	84,733	8,539
Revenue from Operations	1,606	1,207	4,410	8,373	1,500
EBITDA	313	305	930	2,243	343
EBITDA Margin (%)	19.5	25.3	21.1	26.8	22.9
Adj. PAT	44	172	557	1,483	189
Adj. PAT Margin (%)	2.7	14.3	12.6	17.7	12.6
RoE (%)	11.1	9.7	14.1	13.8	12.2
RoCE (%)	15.4	11.8	17.5	14.3	13.9
P/E (x)	171.1	55.2	60.2	55.6	42.8
EV/EBITDA (x)	24.1	31.1	35.5	37.8	24.9
EV/Sales (x)	4.7	7.9	7.5	10.1	5.7

For Paras Healthcare Ltd., RoE, RoCE, Market Cap, P/E(x), EV/EBITDA (x), EV/Sales (x) are calculated on post-issue equity share capital based on the upper price band.

CMP for peer companies is live price of 19th October, 2026.

Source: Bloomberg, RHP, SSL Research

Peer Comparison – KPIs (Jun'26)

Particulars (Rs cr)	Unit	Paras Healthcare	Yatharth Hospital and Trauma Care Services	Global Health	Max Healthcare Institute	Jupiter Life Line Hospitals
Number of hospitals	Number	8	8	6	21	4
Total bed capacity	Number	2,211	2,555	3,737	6,100	1,700
ICU beds	Number	559	NA	956	NA	NA
Operational beds	Number	1,502	1,820	3,037	5,379	1,259
Occupancy	%	69.7%	68.0%	62.6%	75.0%	59.6%
Occupied Bed Days	Number	95,272	NA	1,73,064	NA	NA
Average revenue per occupied bed (ARPOB)	Rs per day	49,352	34,758	70,244	81,900	73,500
Average length of stay (ALOS)	Days	2.8	3.7	2.9	4.1	3.8
In-patient volume	Number	34,354	30,000	60,214	91,326	14,200
Out-patient volume	Number	2,25,734	1,39,000	11,00,928	10,47,000	2,77,300

Source: Bloomberg, RHP, SSL Research

Financial Snapshot

Particulars (Rs cr)	FY24	FY25	FY26	1QFY27
Revenue from Operations	1,129	1,294	1,606	470
<i>YoY growth (%)</i>	-	14.6%	24.1%	27.7%
COGS (incl Stock Adj)	297	337	430	115
Gross Profit	832	957	1,176	355
Gross margin (%)	73.7%	74.0%	73.2%	75.5%
Employee Cost	167	174	182	56
Other Operating Expenses	546	647	681	194
EBITDA	119	136	313	105
EBITDA margins (%)	10.5%	10.5%	19.5%	22.3%
Other Income	35	20	23	8
Interest Exp.	67	91	116	30
Depreciation	81	116	144	35
PBT	7	(50)	76	48
Tax	22	8	32	(2)
PAT	(15)	(58)	44	50
PAT margin (%)	-1.4%	-4.5%	2.7%	10.6%
EPS (Rs)	(1.5)	(5.7)	4.3	4.9
Adj. PAT	(29)	(58)	44	50
Adj. PAT margin (%)	-2.5%	-4.5%	2.7%	10.6%
Adj. EPS	(2.8)	(5.7)	4.3	4.9

Particulars (Rs cr)	FY24	FY25	FY26	1QFY27
Assets				
Net Block	589	646	674	665
Right of use assets	392	521	531	526
Capital WIP	29	38	29	27
Intangible Assets	3	2	1	1
Goodwill	5	5	5	5
Other Non current Assets	88	82	57	130
Current Assets				
Inventories	28	26	32	35
Trade receivables	156	235	350	448
Cash and Bank Balances	160	206	303	299
Other Current Assets	29	51	91	67
Total Current Assets	374	518	775	849
Current Liabilities & Provisions				
Trade payables	137	191	208	261
Other current liabilities	65	91	61	53
Short-term provisions	4	4	3	3
Total Current Liabilities	206	286	272	318
Net Current Assets	168	232	503	531
Total Assets	1,272	1,525	1,800	1,885
Liabilities				
Share Capital	10	10	10	10
Reserves and Surplus	329	271	385	435
Total Shareholders Funds	339	280	395	445
Total Debt	548	728	854	889
Long Term Provisions	7	7	9	10
Lease Liabilities	376	504	540	541
Other Long Term Liabilities	0	1	1	0
Net Deferred Tax Liability	2	4	2	-
Total Liabilities	1,272	1,525	1,800	1,885

Particulars (Rs cr)	FY24	FY25	FY26	1QFY27
Cash flow from Operating Activities	92	86	164	64
Cash flow from Investing Activities	(194)	(147)	(239)	(92)
Cash flow from Financing Activities	94	83	86	6
Free Cash Flow	(105)	(50)	(6)	33
Capex	(198)	(137)	(169)	(32)

RATIOS			
Particulars	FY24	FY25	FY26
Profitability			
Return on Assets	(1.9%)	(3.2%)	2.1%
Return on Capital Employed	8.3%	4.1%	15.4%
Return on Equity	(8.5%)	(20.7%)	11.1%
Margin Analysis			
Gross Margin	73.7%	74.0%	73.2%
EBITDA Margin	10.5%	10.5%	19.5%
Net Profit Margin	(2.5%)	(4.5%)	2.7%
Short-Term Liquidity			
Current Ratio (x)	0.9	0.9	1.2
Quick Ratio (x)	0.9	0.9	1.1
Days Sales Outstanding	51	66	79
Days Inventory Outstanding	9	7	7
Days Payables	44	54	47
Fixed asset turnover (x)	1.2	1.1	1.3
Debt-service coverage (x)	0.1	0.0	0.2
Long-Term Solvency			
Total Debt / Equity (x)	1.6	2.6	2.2
Interest Coverage Ratio (x)	1.1	0.4	1.7
Valuation Ratios*			
EV/EBITDA (x)	62.0	55.2	24.1
P/E (x)	(243.7)	(120.7)	159.7
P/B (x)	20.7	25.0	17.7
EV/Sales (x)	6.5	5.8	4.7
Market Cap/Sales (x)	6.2	5.4	4.4

*Valuation ratios are based on pre-issue capital at the upper price band

Source: RHP, SBICAP Securities Research

SBICAP Securities Limited

(CIN): U65999MH2005PLC155485

SEBI Registration No.: Stock Broker: INZ000200032 | DP Registration No.: IN-DP-314-2017

Research Analyst: INH000000602 | IRDA: CA0103 | PFRDA Registration No: POP 26092018

Registered & Corporate Office: Marathon Futurex, Unit No. 1201, B-Wing, 12th Floor, N M Joshi Marg,
Mafatlal Mill Compound, Lower Parel East, Mumbai 400013 .

For any information contact us: **(022) 6854 5555 | E-mail: helpdesk@sbicapsec.com | Web: www.sbicapsec.com**

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. | Research Disclaimer: https://bit.ly/R_disclaimer02 | This is for education/information purposes only. | Trade Name : -SBICAP Securities Limited | SEBI registration Number :- Stock Broker: INZ000200032 | DP Registration No.: IN-DP-314-2017 Research Analyst : INH000000602, IRDAI Corporate Agency Reg. No. CA0103; AMFI Reg. No. ARN-0011; PFRDA Reg. No. POP26092018.

DISCLOSURES & DISCLAIMERS:

Analyst Certification: The views expressed in this research report ("Report") accurately reflect the personal views of the research analysts ("Analysts") employed by SBICAP Securities Limited (SSL) about any and all of the subject issuer(s) or company(ies) or securities. This report has been prepared based upon information available to the public and sources, believed to be reliable. I/We also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

The Analysts engaged in preparation of this Report or his/her relative:-

- (a) do not have any financial interests in the subject company mentioned in this Report; (b) do not own 1 or more of the equity securities of the subject company mentioned in the report as of the last day of the month preceding the publication of the research report; (c) do not have any material conflict of interest at the time of publication of the Report.

The Analysts engaged in preparation of this Report:-


- (a) have not received any compensation from the subject company in the past twelve months; (b) have not managed or co-managed public offering of securities for the subject company in the past twelve months; (c) have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (d) have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months; (e) has not received any compensation or other benefits from the subject company or third party in connection with the Report; (f) has not served as an officer, director or employee of the subject company; (g) is not engaged in market making activity for the subject company.

<u>Name</u>	<u>Qualification</u>	<u>Designation</u>
Fundamental Team		
Sunny Agrawal	B.E., MBA (Finance)	DVP - Fundamental Research
Rajesh Gupta	PGDBM (Finance), MA (Bus. Eco)	AVP - Fundamental Research
Monica Chauhan	C.A.	Research Analyst - Equity Fundamentals
Harsh Vasa	C.A.	Research Analyst - Equity Fundamentals
Sumeet Shah	B.E., CFA	Research Analyst - Equity Fundamentals
Shubham Purohit	BMS (Finance)	Research Associate - Equity Fundamentals
Vinit Mishra	B.Com	Research Associate - Equity Fundamentals
Avijit Sheet	MBA (Finance)	Research Associate - Equity Fundamentals
Siddhesh Nanal	MSc (Finance)	Research Associate - Equity Fundamentals
Aldrin Viegas	BFM	Research Associate - Equity Fundamentals
Technical & Derivatives Team		
Sudeep Shah	MMS-Finance	VP- Technical & Derivative Research
Gautam Upadhyaya	MBA (Finance)	Research Analyst - Equity Derivatives
Vinayak Gangule	BE (IT)	Research Analyst - Equity Technicals
Ashwin Ramani	B.Com	Research Analyst - Equity Technicals
Sagar Peswani	B.Tech (ECE)	Research Associate - Equity Technicals
Kalpesh Mangade	B.Com	MIS Analyst - Retail Research

For other Disclosures please visit: https://bit.ly/R_disclaimer02



Sudeep Shah
VP – Technical & Derivative Research



Sunny Agrawal
DVP – Fundamental Research